Palbociclib in the treatment of metastatic breast cancer

Abstract

This case report deals with a young BRCA2 positive patient with bilateral metastatic breast cancer who underwent treatment with CDK4 / 6 inhibitors at our workplace. Despite repeated treatment discontinuity and dose reduction, palbociclib achieved above-standard results.

Keywords

• CDK4 / 6 inhibitors
• breast cancer
• letrozole
• luminal B
• palbociclib